• Background
• Potential Benefits of Companion Diagnostics
• Pitfalls of Personalized Medicine
• Scope and Methodology
• Market Factors and Estimates
• Drivers for Companion Diagnostics
• Assumptions
• Important Trends
• Possible Tactic: Royalty Model

• Personalized Medicine
• Potential Benefits
• Privacy and Public Perception
• Biomarkers and Companion Diagnostics
• Types of Biomarkers
• Chapter Three: Applications of Companion

• Pharmacogenetics and Pharmacogenomics
• Historical Basis
• Current Techniques
• Requirements
• Cost-Effectiveness
• Applications
• The Cytochrome System
• Cancer
• Amgen
• Uams Multiple Myeloma Project
• Dakoassay for Top2a
• Ge and Eli Lilly
• Epigenomics and Abbott
• Celera and Merk
• Biomerieiux and Ipsen
• Acute Lymphoblastic Leukemia
• Regulatory Agencies
• Applications of Genome More Challenging than Expected
• Cardiovascular Disease
• Ras Polymorphisms with Drug Effectiveness
• Pgp
• Thiazide Diuretics
• 825t Allele
• Hit
• Statins
• Psychiatry and Pharmacogenetics/Pharmacogenomics
• Is Herceptin A Paradigm?
• A Balancing Act between The Players

• Estimating Market Potential
• Associated Testing
• The Needs of Pharma and of Diagnostic Companies
• Questions Determining Companion Diagnostics Growth
• A Partial Change in Attitude
• Intellectual Property
• Cancer Market Potential Estimate
• Ideal Market Potential - Cancer, Heart Disease, Psychiatric
• Source: Kalorama Information
• Challenges Unique to Companion Diagnostics
• Privacy Concerns
• Fear of Learning about Diseases
• Use of Remnant Samples
• Avoiding Pitfalls of Market Calculation
• Companion Diagnostics Not Linked to Molecular Diagnostics
• Demonic and Snp Analysis
• Considering Time of Cooperative Development
• Market Realities to Consider
• Possible Tactic: Royalty Model

• Overview
• Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
• Affymetrix, Inc.
• Agilent Technologies, Inc
• Althea Technologies, Inc.
• Curidium Medica Plc
• Dako
• Gen Probe
• Genzyme Corporation
• Ipsogen Sas
• Lipomics Technologies, Inc.
• Osmetech Plc
• Perlegen Sciences
• Provista Life Sciences
• Qiagen Nv
• Singulex, Inc.
• Theranostics Health
• Ventana Medical Systems

• First Conclusion
• Implications:
• Second Conclusion
• Implications:
• Third Conclusion
• Implications:
• Fourth Conclusion
• Implications:
• Fifth Conclusion
• Implications:
• Sixth Conclusion
• Implications:
• Seventh Conclusion
• Implications:
• Eighth Conclusion
• Implications:
• Ninth Conclusion
• Implications:
• Tenth Conclusion
• Implications:

• Table 1-1: Market Projections for Companion Diagnostics*
• in The United States: 2008 - 2018
• Figure 1-1: Market Projection Trends for Companion Diagnostics
• in The United States: 2008 - 2018

• Table 3-1 Companion Diagnostics Groups
• Table 3-3: Frequency of Recessive Traits
• Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
• Table 3-5: Recent Activities in Companion Diagnostics
• Chapter Four: Major World Market Factors and

• Table 4-1: The Ideal Potential Companion Diagnostics Markets for
• Cancer Therapeutics: 2008
• Figure 4-1: The Ideal Potential Companion Diagnostics Markets
• for Cancer Therapeutics: 2008
• Table 4-2: The Ideal Potential Companion Diagnostics Markets for
• Therapeutics Addressing The Top Four, High-Profile Cancers: 2008
• Figure 4-2: The Ideal Potential Companion Diagnostics Markets for
• Therapeutics Addressing The Top Four, High-Profile Cancers: 2008
• Figure 4-3: The Ideal Companion Diagnostics Market
• (Ideal vs. Likely to Benefit)
• Figure 4-4 Subset of Ideal Market Likely to Benefit from Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market)
• Table 4-3: Market Projections for Companion Diagnostics* in
• The United States: 2008 - 2018
• Figure 4-1: Market Projection Trends for Companion Diagnostics*
• in The United States: 2008 - 2018

• Table 6-1: Hypothetical Cancer Therapy Outcome Based on Associated Genes

Buy this report >>